Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Monday

Lyell Immunopharma (NASDAQ:LYEL) is expected to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect Lyell Immunopharma to post earnings of ($0.19) per share for the quarter.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The company had revenue of $0.01 million for the quarter. On average, analysts expect Lyell Immunopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lyell Immunopharma Trading Down 1.9 %

Shares of Lyell Immunopharma stock opened at $0.46 on Friday. The company has a fifty day simple moving average of $0.53 and a 200-day simple moving average of $0.71. Lyell Immunopharma has a 12-month low of $0.39 and a 12-month high of $2.88. The stock has a market cap of $136.21 million, a price-to-earnings ratio of -0.58 and a beta of -0.26.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a report on Wednesday, April 16th.

Insider Buying and Selling at Lyell Immunopharma

In other Lyell Immunopharma news, Director Sumant Ramachandra acquired 200,000 shares of the stock in a transaction on Friday, March 21st. The shares were bought at an average cost of $0.58 per share, with a total value of $116,000.00. Following the transaction, the director now owns 200,000 shares of the company’s stock, valued at approximately $116,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard Klausner bought 158,000 shares of Lyell Immunopharma stock in a transaction dated Friday, March 14th. The stock was acquired at an average cost of $0.60 per share, with a total value of $94,800.00. Following the completion of the acquisition, the director now directly owns 843,365 shares of the company’s stock, valued at approximately $506,019. The trade was a 23.05 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 768,640 shares of company stock worth $449,508. 25.10% of the stock is owned by insiders.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.